6.78 USD
-0.23 (-3.28%)
6.7608 USD
-0.02 (-0.28%)
Overall CRMD gets a fundamental rating of 6 out of 10. We evaluated CRMD against 190 industry peers in the Pharmaceuticals industry. CRMD has only an average score on both its financial health and profitability. An interesting combination arises when we look at growth and value: CRMD is growing strongly while it also seems undervalued. These ratings could make CRMD a good candidate for value and growth investing.
1. Profitability
1.1 Basic Checks
- CRMD had positive earnings in the past year.
- In the past year CRMD had a positive cash flow from operations.
- In the past 5 years CRMD always reported negative net income.
- In the past 5 years CRMD always reported negative operating cash flow.
1.2 Ratios
- Looking at the Return On Assets, with a value of 21.64%, CRMD belongs to the top of the industry, outperforming 97.89% of the companies in the same industry.
- CRMD's Return On Equity of 43.43% is amongst the best of the industry. CRMD outperforms 97.37% of its industry peers.
- The Return On Invested Capital of CRMD (13.31%) is better than 92.63% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 21.64% | ||
| ROE | 43.43% | ||
| ROIC | 13.31% |
ROA(3y)-39.81%
ROA(5y)-41%
ROE(3y)-47.06%
ROE(5y)-47.18%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- CRMD's Profit Margin of 75.83% is amongst the best of the industry. CRMD outperforms 98.42% of its industry peers.
- CRMD has a better Operating Margin (48.51%) than 98.95% of its industry peers.
- Looking at the Gross Margin, with a value of 92.61%, CRMD belongs to the top of the industry, outperforming 94.21% of the companies in the same industry.
- In the last couple of years the Gross Margin of CRMD has grown nicely.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 48.51% | ||
| PM (TTM) | 75.83% | ||
| GM | 92.61% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y63.88%
GM growth 5YN/A
2. Health
2.1 Basic Checks
- With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), CRMD is creating some value.
- The number of shares outstanding for CRMD has been increased compared to 1 year ago.
- Compared to 5 years ago, CRMD has more shares outstanding
- CRMD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
- Based on the Altman-Z score of 1.47, we must say that CRMD is in the distress zone and has some risk of bankruptcy.
- The Altman-Z score of CRMD (1.47) is comparable to the rest of the industry.
- CRMD has a debt to FCF ratio of 1.96. This is a very positive value and a sign of high solvency as it would only need 1.96 years to pay back of all of its debts.
- The Debt to FCF ratio of CRMD (1.96) is better than 93.68% of its industry peers.
- A Debt/Equity ratio of 0.39 indicates that CRMD is not too dependend on debt financing.
- CRMD has a Debt to Equity ratio of 0.39. This is in the lower half of the industry: CRMD underperforms 61.05% of its industry peers.
- Although CRMD does not score too well on debt/equity it has very limited outstanding debt, which is well covered by the FCF. We will not put too much weight on the debt/equity number as it may be because of low equity, which could be a consequence of a share buyback program for instance. This needs to be investigated.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.39 | ||
| Debt/FCF | 1.96 | ||
| Altman-Z | 1.47 |
ROIC/WACC1.41
WACC9.43%
2.3 Liquidity
- CRMD has a Current Ratio of 1.94. This is a normal value and indicates that CRMD is financially healthy and should not expect problems in meeting its short term obligations.
- CRMD has a Current ratio of 1.94. This is in the lower half of the industry: CRMD underperforms 62.63% of its industry peers.
- A Quick Ratio of 1.73 indicates that CRMD should not have too much problems paying its short term obligations.
- CRMD has a Quick ratio (1.73) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.94 | ||
| Quick Ratio | 1.73 |
3. Growth
3.1 Past
- The Earnings Per Share has grown by an impressive 354.32% over the past year.
- CRMD shows a strong growth in Revenue. In the last year, the Revenue has grown by 1647.68%.
- The Revenue has been growing by 174.29% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)354.32%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%2620%
Revenue 1Y (TTM)1647.68%
Revenue growth 3Y511.63%
Revenue growth 5Y174.29%
Sales Q2Q%810.21%
3.2 Future
- The Earnings Per Share is expected to grow by 64.75% on average over the next years. This is a very strong growth
- Based on estimates for the next years, CRMD will show a very strong growth in Revenue. The Revenue will grow by 65.90% on average per year.
EPS Next Y857.27%
EPS Next 2Y210.43%
EPS Next 3Y105.83%
EPS Next 5Y64.75%
Revenue Next Year684.25%
Revenue Next 2Y232.48%
Revenue Next 3Y118.98%
Revenue Next 5Y65.9%
3.3 Evolution
- The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
- Based on the Price/Earnings ratio of 3.29, the valuation of CRMD can be described as very cheap.
- CRMD's Price/Earnings ratio is rather cheap when compared to the industry. CRMD is cheaper than 96.84% of the companies in the same industry.
- The average S&P500 Price/Earnings ratio is at 27.47. CRMD is valued rather cheaply when compared to this.
- With a Price/Forward Earnings ratio of 2.69, the valuation of CRMD can be described as very cheap.
- CRMD's Price/Forward Earnings ratio is rather cheap when compared to the industry. CRMD is cheaper than 97.89% of the companies in the same industry.
- When comparing the Price/Forward Earnings ratio of CRMD to the average of the S&P500 Index (24.26), we can say CRMD is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 3.29 | ||
| Fwd PE | 2.69 |
4.2 Price Multiples
- Based on the Enterprise Value to EBITDA ratio, CRMD is valued cheaper than 96.32% of the companies in the same industry.
- Based on the Price/Free Cash Flow ratio, CRMD is valued cheaper than 95.26% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 7.18 | ||
| EV/EBITDA | 5.87 |
4.3 Compensation for Growth
- CRMD's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
- CRMD has a very decent profitability rating, which may justify a higher PE ratio.
- CRMD's earnings are expected to grow with 105.83% in the coming years. This may justify a more expensive valuation.
PEG (NY)0
PEG (5Y)N/A
EPS Next 2Y210.43%
EPS Next 3Y105.83%
5. Dividend
5.1 Amount
- No dividends for CRMD!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
6.78
-0.23 (-3.28%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-12 2025-11-12/bmo
Earnings (Next)03-23 2026-03-23/amc
Inst Owners61.7%
Inst Owner Change0.27%
Ins Owners7%
Ins Owner Change3.1%
Market Cap534.20M
Revenue(TTM)214.30M
Net Income(TTM)162.50M
Analysts83.08
Price Target19.38 (185.84%)
Short Float %23.04%
Short Ratio5.83
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)75.14%
Min EPS beat(2)58.8%
Max EPS beat(2)91.47%
EPS beat(4)4
Avg EPS beat(4)54.36%
Min EPS beat(4)13.12%
Max EPS beat(4)91.47%
EPS beat(8)7
Avg EPS beat(8)32.13%
EPS beat(12)8
Avg EPS beat(12)21.06%
EPS beat(16)12
Avg EPS beat(16)20.34%
Revenue beat(2)2
Avg Revenue beat(2)16.66%
Min Revenue beat(2)14.48%
Max Revenue beat(2)18.84%
Revenue beat(4)4
Avg Revenue beat(4)13.08%
Min Revenue beat(4)3.69%
Max Revenue beat(4)18.84%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-7.32%
EPS NQ rev (1m)3%
EPS NQ rev (3m)14.87%
EPS NY rev (1m)-0.12%
EPS NY rev (3m)54.34%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)23.88%
Revenue NY rev (1m)0%
Revenue NY rev (3m)25.39%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 3.29 | ||
| Fwd PE | 2.69 | ||
| P/S | 2.49 | ||
| P/FCF | 7.18 | ||
| P/OCF | 7.13 | ||
| P/B | 1.43 | ||
| P/tB | N/A | ||
| EV/EBITDA | 5.87 |
EPS(TTM)2.06
EY30.38%
EPS(NY)2.52
Fwd EY37.17%
FCF(TTM)0.94
FCFY13.93%
OCF(TTM)0.95
OCFY14.03%
SpS2.72
BVpS4.75
TBVpS-0.42
PEG (NY)0
PEG (5Y)N/A
Graham Number14.84
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 21.64% | ||
| ROE | 43.43% | ||
| ROCE | 16.84% | ||
| ROIC | 13.31% | ||
| ROICexc | 14.63% | ||
| ROICexgc | 53.33% | ||
| OM | 48.51% | ||
| PM (TTM) | 75.83% | ||
| GM | 92.61% | ||
| FCFM | 34.73% |
ROA(3y)-39.81%
ROA(5y)-41%
ROE(3y)-47.06%
ROE(5y)-47.18%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y63.88%
GM growth 5YN/A
F-Score5
Asset Turnover0.29
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.39 | ||
| Debt/FCF | 1.96 | ||
| Debt/EBITDA | 1.34 | ||
| Cap/Depr | 12.94% | ||
| Cap/Sales | 0.26% | ||
| Interest Coverage | 3893.29 | ||
| Cash Conversion | 69.29% | ||
| Profit Quality | 45.8% | ||
| Current Ratio | 1.94 | ||
| Quick Ratio | 1.73 | ||
| Altman-Z | 1.47 |
F-Score5
WACC9.43%
ROIC/WACC1.41
Cap/Depr(3y)258.21%
Cap/Depr(5y)648.52%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)354.32%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%2620%
EPS Next Y857.27%
EPS Next 2Y210.43%
EPS Next 3Y105.83%
EPS Next 5Y64.75%
Revenue 1Y (TTM)1647.68%
Revenue growth 3Y511.63%
Revenue growth 5Y174.29%
Sales Q2Q%810.21%
Revenue Next Year684.25%
Revenue Next 2Y232.48%
Revenue Next 3Y118.98%
Revenue Next 5Y65.9%
EBIT growth 1Y303.98%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year815.55%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y319.01%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y321.67%
OCF growth 3YN/A
OCF growth 5YN/A
CORMEDIX INC / CRMD FAQ
What is the fundamental rating for CRMD stock?
ChartMill assigns a fundamental rating of 6 / 10 to CRMD.
What is the valuation status for CRMD stock?
ChartMill assigns a valuation rating of 10 / 10 to CORMEDIX INC (CRMD). This can be considered as Undervalued.
Can you provide the profitability details for CORMEDIX INC?
CORMEDIX INC (CRMD) has a profitability rating of 6 / 10.
What is the valuation of CORMEDIX INC based on its PE and PB ratios?
The Price/Earnings (PE) ratio for CORMEDIX INC (CRMD) is 3.29 and the Price/Book (PB) ratio is 1.43.
What is the financial health of CORMEDIX INC (CRMD) stock?
The financial health rating of CORMEDIX INC (CRMD) is 5 / 10.